Hospitalization provides an opportunity for physicians to optimize heart failure treatment to reduce the likelihood of hospital readmission and death, reduce the burden of hospitalizations, and improve outcomes for patients living with heart failure.

Novartis and AveXis combine, aiming to transform the care of SMA, the #1 genetic cause of infant mortality.

The factsheet “Strengthening our Global Health & Corporate Responsibility function” provides an overview of our Global Health & Corporate Responsibility governance, structure, strategic priorities and commitments.

The fact sheet “Building trust with society: our priorities” provides key highlights around 4 areas: pricing and access to medicines; global health challenges; ethical standards; and corporate responsibility.

Although breast cancer is one of the most visible and supported diseases in the world, the majority of public focus goes toward prevention, early detection and survival.

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer and accounts for 90% of all cancerous kidney tumors.

Global survey of Chronic Myeloid Leukemia (CML) treaters across 9 countries and 4 continents suggests many physicians are ambitiously managing the disease despite its chronic nature.

This fact sheet provides information on Novartis Access, a social business model that brings affordable treatments to patients suffering from chronic diseases in low- and lower-middle-income countries (LMICs). 

Reimagining the fight against Chagas disease: Although Chagas disease was discovered more than a century ago, it remains a major public health challenge – and current tools to fight the disease are outdated and inadequate.

Novartis has been in the front ranks of a revolution in the treatment of malaria, launching the first fixed-dose artemisinin-based combination therapy (ACT) in 1999 and the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV) in 2009.

Reimagining the management of sickle cell disease in Africa. Sickle cell disease is a hereditary and life-threatening condition that causes ongoing vascular damage and repeated injury to blood vessels and organs. This lifelong illness often takes an extreme emotional, physical, and financial toll on patients and their families.

The fight against leprosy is one of the greatest public health successes in history. For more than 30 years, Novartis and the Novartis Foundation have been working with partners around the world to eliminate leprosy.